246 related articles for article (PubMed ID: 12234264)
1. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma.
Chiriva-Internati M; Wang Z; Salati E; Wroblewski D; Lim SH
Scand J Immunol; 2002 Oct; 56(4):429-33. PubMed ID: 12234264
[TBL] [Abstract][Full Text] [Related]
2. Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk.
Chiriva-Internati M; Wang Z; Xue Y; Bumm K; Hahn AB; Lim SH
Eur J Immunol; 2001 Aug; 31(8):2277-83. PubMed ID: 11477539
[TBL] [Abstract][Full Text] [Related]
3. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma.
Chiriva-Internati M; Wang Z; Salati E; Bumm K; Barlogie B; Lim SH
Blood; 2002 Aug; 100(3):961-5. PubMed ID: 12130509
[TBL] [Abstract][Full Text] [Related]
4. Tumor vaccine for ovarian carcinoma targeting sperm protein 17.
Chiriva-Internati M; Wang Z; Salati E; Timmins P; Lim SH
Cancer; 2002 May; 94(9):2447-53. PubMed ID: 12015770
[TBL] [Abstract][Full Text] [Related]
5. Identification of a sperm protein 17 CTL epitope restricted by HLA-A1.
Chiriva-Internati M; Wang Z; Pochopien S; Salati E; Lim SH
Int J Cancer; 2003 Dec; 107(5):863-5. PubMed ID: 14566839
[TBL] [Abstract][Full Text] [Related]
6. Umbilical cord blood-derived dendritic cells infected by adenovirus for SP17 expression induce antigen-specific cytotoxic T cells against NSCLC cells.
Liu Y; Tian X; Jiang S; Ren X; Liu F; Yang J; Chen Y; Jiang Y
Cell Immunol; 2015; 298(1-2):18-24. PubMed ID: 26300426
[TBL] [Abstract][Full Text] [Related]
7. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
[TBL] [Abstract][Full Text] [Related]
8. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
[TBL] [Abstract][Full Text] [Related]
9. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
10. Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway.
Chiriva-Internati M; Du J; Cannon M; Barlogie B; Yi Q
Br J Haematol; 2001 Feb; 112(2):410-20. PubMed ID: 11167840
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation.
Kurokawa T; Fischer K; Bertz H; Hoegerle S; Finke J; Mackensen A
Int J Cancer; 2002 Sep; 101(1):52-60. PubMed ID: 12209588
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.
Mutis T; Verdijk R; Schrama E; Esendam B; Brand A; Goulmy E
Blood; 1999 Apr; 93(7):2336-41. PubMed ID: 10090944
[TBL] [Abstract][Full Text] [Related]
13. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.
Wen YJ; Min R; Tricot G; Barlogie B; Yi Q
Blood; 2002 May; 99(9):3280-5. PubMed ID: 11964294
[TBL] [Abstract][Full Text] [Related]
14. A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults.
LaVoy EC; Bollard CM; Hanley PJ; Blaney JW; O'Connor DP; Bosch JA; Simpson RJ
Exerc Immunol Rev; 2015; 21():144-53. PubMed ID: 25826370
[TBL] [Abstract][Full Text] [Related]
15. Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma.
Jalili A; Ozaki S; Hara T; Shibata H; Hashimoto T; Abe M; Nishioka Y; Matsumoto T
Blood; 2005 Nov; 106(10):3538-45. PubMed ID: 16037388
[TBL] [Abstract][Full Text] [Related]
16. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.
van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H
Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741
[TBL] [Abstract][Full Text] [Related]
17. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
[TBL] [Abstract][Full Text] [Related]
18. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
19. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
20. Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy.
Nolte A; Scheffold C; Slotty J; Huenefeld C; Schultze JL; Grabbe S; Berdel WE; Kienast J
J Immunother; 2003; 26(3):257-69. PubMed ID: 12806279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
